X0508 4 2023-07-14 0001842939 ALPHA HEALTHCARE ACQUISITION CORP III CTCX 0001984167 Godward Donna C/O CARMELL THERAPEUTICS CORPORATION 2403 SIDNEY STREET, SUITE 300 PITTSBURGH PA 15203 0 1 0 0 Chief Quality Officer 0 Common Stock 2023-07-14 4 A 0 37296 A 37296 D Stock Option (right to buy) 1.79 2023-07-14 4 A 0 2090 A 2027-06-20 Common Stock 2090 2090 D Stock Option (right to buy) 2.27 2023-07-14 4 A 0 5318 A 2029-07-19 Common Stock 5318 5318 D Stock Option (right to buy) 2.11 2023-07-14 4 A 0 119098 A 2031-09-23 Common Stock 119098 119098 D Stock Option (right to buy) 2.11 2023-07-14 4 A 0 12309 A 2032-07-13 Common Stock 12309 12309 D Stock Option (right to buy) 2.60 2023-07-14 4 A 0 12309 A 2032-12-15 Common Stock 12309 12309 D On July 14, 2023, Alpha Healthcare Acquisition Corp. III ("ALPA") consummated a business combination (the "Business Combination") by and among ALPA, Candy Merger Sub, Inc., a Delaware Corporation ("Merger Sub") and Carmell Regen Med Corporation, a Delaware corporation ("Legacy Carmell"), ALPA changed its name to "Carmell Therapeutics Corporation" and Merger Sub merged with and into Legacy Carmell. As part of the Business Combination, each share of common stock of Legacy Carmell was exchanged for 0.06154 shares of common stock of Carmell Therapeutics Corporation. Options are fully vested and exercisable. Options to purchase 5,318 shares of common stock of Legacy Carmell granted on July 19, 2019, which vest as follows: 25% vested on July 19, 2020, July 19, 2021 and July 19, 2022 and the remaining 25% becomes vested on July 19, 2023. Options to purchase 119,098 shares of common stock of Legacy Carmell granted on September 23, 2021, which vest as follows: 25% vested on September 23, 2022 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date. Options to purchase 12,309 shares of common stock of Legacy Carmell granted on July 13, 2023 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date. Options to purchase 12,309 shares of common stock of Legacy Carmell granted on December 15, 2022, which vest as follows: 25% vesting on December 22, 2023 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date. As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation. /s/ Randolph W. Hubbell, Attorney-in-Fact 2023-07-18